- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03916510
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer (CEDAR)
A Phase 1 Trial of the Safety, Tolerability and Biological Effects of Intravenous Enadenotucirev, a Novel Oncolytic Virus, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer
The use of chemoradiotherapy (CRT), in combination with surgery is the standard of care in the treatment of locally advanced rectal cancer. However some patients don't respond well to radiation.
More advanced radiotherapy techniques, that result in fewer toxicities, means that we are now able to combine new anti-cancer agents into standard treatment. Targeting the tumour early in this way has the potential to improve response rates.
Enadenotucirev is a specific type of anti-cancer virus that only targets cancer cells. It acts in the same way as any virus and can only survive by replicating inside cancer cells and not normal, non-cancerous cells. This means that it can selectively target and destroy tumours, without directly affecting normal cells. It also has the ability to attract cells from the body's immune system to help fight the cancer.
The addition of enadenotucirev to standard chemoradiotherapy treatment may have a combined effect on the cancer cells with potentially few, additional side effects.
This trial aims to determine the optimal dose and frequency of the virus to give by gradually increasing the number of doses each successive patient receives, and then increasing the dose of the virus itself. Each patient will receive a minimum of 3 doses, up to a maximum of 6, spread over the course of their 5 week standard chemoradiotherapy treatment. Patients will be closely monitored at all times to ensure that with each dosing group, there aren't excessive side effects.
Patients will then undergo surgery as part of their standard of care and be followed up for up to 4-6 weeks post-surgery.
This trial aims to determine the optimal dose and frequency that can then be used in future studies with the possibility of exploring the addition of Enadenotucirev to other chemoradiotherapy treatments.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At present identifying novel radiosensitising agents in colorectal cancer is an area of high need for patients considering sphincter preserving surgery or needing down staging to facilitate surgery.
Although the combination of Enadenotucirev with chemoradiation is novel, there is a wealth of evidence to support the rationale for combining this class of agent with radiation and chemotherapy.
Enadenotucirev is a group B oncolytic virus under development for the systemic treatment of metastatic or advanced epithelial tumours. Enadenotucirev is a chimeric adenovirus type 11p (Adp/adenovirus type 3 (Ad3) virus, discovered through a process of bio-selection from a library of chimeric viruses produced from a pool of adenoviruses from seven different serotypes utilizing human HT-29 colorectal cancer (CRC) cells.
Enadenotucirev shows selective and potent toxicity in humans carcinoma cells with only very limited or no toxicity to normal (non-cancerous) human cells. Other than humans, there is no known permissive species for Enadenotucirev. The principle advantage of oncolytic therapy is that the virus replicates only in diseased cells meaning that the concentration of drug is amplified at the site of pathology so that it is higher in the tumour than in healthy tissue. Virus particles spread from cell to cell within a tumour nodule until they reach non-permissive normal tissues, in principle destroying all viable tumour cells they encounter.
While the overall understanding of the mechanism of action of Enadenotucirev in humans is still under investigation, it is now well established from non-clinical and clinical studies that the mechanism of anti-cancer efficacy of oncolytic viruses not only involves direct infection and lysis of tumour cells, but that immune responses stimulated via an increased release of tumour-associated antigens and immune-inflammatory activation signals play a key role.
CEDAR is dual endpoint, dose escalation phase 1 trial using a time to event continual reassessment method (TiTECRM). Response and Toxicity endpoints will be combined in dose escalation models to identify the optimal dose schedule. Dose decisions are made using the statistical model instead of just using the data from that particular dose, as in the case of 3+3 model, meaning it uses all available data to make a dose decision.
This primary objective is to determine the optimal dose and frequency of the virus by firstly gradually increasing the number of doses each successive patient receives, and then increasing the dose of the virus itself. All participants will receive 3 loading doses in weeks 1-2, prior to initiation of standard chemoradiotherapy. Further doses of Enadenotucirev will either be given after or during and after standard chemoradiotherapy and this is dependent on which of the 4 different dose groups they are assigned to. The dose given will vary between either 1x1012 Viral Particles (VP) or 3x1012vp.
Each patient will receive a minimum of 3 doses, up to a maximum of 6, spread over the course of 9 weeks. Patients will be closely monitored at all times to ensure that with each dosing group, there aren't excessive side effects.
Patients will then undergo surgery as part of their standard of care and be followed up for 4-6 weeks after surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Steven Davis
- Phone Number: +44 (0)1865 617087
- Email: octo-cedar@oncology.ox.ac.uk
Study Locations
-
-
-
Cardiff, United Kingdom, CF14 2TL
- Velindre Cancer Centre
-
Glasgow, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Centre
-
London Borough of Sutton, United Kingdom, SM2 5PT
- Royal Marsden NHS Foundation Trust
-
Oxford, United Kingdom, OX3 7LE
- The Churchill Hospital, Oxford University Hospitals Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed invasive adenocarcinoma of the rectum
- Locally advance colorectal cancer as defined by pelvic MRI with a threatened circumferential resection margin (cT3mrf+ve), or inclusion of an adjacent organ, or low tumours at/below the level of the levators or enlarged pelvic side wall nodes or selected by the multidisciplinary team MDT for treatment with neoadjuvant (chemo)radiotherapy, regardless of TNM classification
- Patients with oligometastatic disease suitable for radical treatment are permitted provided that the site specific MDT deems them suitable for chemoradiation
- Male or female, Age ≥ 18 years
- ECOG performance score of 0 - 1
- The patient is willing and able to comply with the protocol scheduled biopsy, follow-up visits and examinations for the duration of the trial.
- Written (signed and dated) informed consent
Adequate renal function demonstrated by:
- Adequate ≤1.5 ULN and estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m (measured creatinine clearance ≥60 mL/min) and
Urine dipstick for proteinuria at screening and baseline negative or trace. Patients may be included with results of 1+ if they have a spot urinary albumin creatinine ratio (ACR) of either:
(i) ≤3 mg/mmol or (ii) >3 mg/mmol with a 24 hour urinary protein <1.0 g/24 hours and
- Serum complement C3 and C4 within the normal range
Haematological and Biochemical indices within the ranges shown below:
- Haemoglobin: ≥90 g/L
- Absolute neutrophil count: ≥1.5x10^9/L
- Platelet count: ≥100x10^9/L
- Bilirubin: < 1.5 upper limit of normal
- Aspartate transaminase and/or alanine transaminase: ≤3 x upper limit of normal
- INR: ≤1.5
- aPTT: within laboratory normal range
Exclusion Criteria:
- Pregnant or breast-feeding women, or women of childbearing potential unless effective methods of contraception are used.
- Pulmonary lymphangitis (if metastatic disease present)
Past medical history:
- Known history or evidence of significant immunodeficiency due to underlying illness and/or medication (e.g. systemic corticosteroids, or other immunosuppressive medications including cyclosporine, azathioprine, interferons in the 4 weeks before the first dose of trial treatment)
- Splenectomy
- Prior allogeneic or autologous bone marrow or organ transplantation
- Patients with a history of, or active, known or suspected auto-immune disease or a syndrome that requires systemic or immunosuppressive agents; patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune disease only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
- History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or evidence of active pneumonia or pneumonitis on computed tomography scan
- Active viral disease or known positive serology for HIV, hepatitis B or hepatitis C
- Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0°C associated with a clinical diagnosis of active infection
- Prior pelvic radiotherapy
- Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions
- Uncontrolled cardiorespiratory comorbidity (e.g. severe pulmonary fibrosis, inadequately controlled angina or myocardial infarction in the last 6 months)
- Major disturbance in bowel function (e.g. severe incontinence, Crohn's disease, >6 loperamide/day), risk of bowel obstruction due to tumour - exception defunctioning colostomy performed
- Treatment with any COVID-19 vaccine in the 28 days before the first dose of enadenotucirev, unless the vaccine is known to not be based on an adenoviral vector (e.g. mRNA vaccines)
- Treatment with any vaccine (including known non-adenoviral COVID-19 vaccines) in the 7 days before first dose of enadenotucirev
- Use of the following anti-viral agents: ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to the first dose of trial treatment
- Treatment with any other investigational agent, or participation in another interventional clinical trial within 28 days prior to enrolment. In follow up for an interventional trials and observational studies are allowed
- History of DVT or pulmonary embolus in the 12 months before the first dose of study of study treatment
- History of significant bleeding requiring hospitalisation in the 12 months before the first dose of study treatment
- Patients receiving therapeutic or prophylactic anticoagulation therapy
- Known dihydropyrimidine dehydrogenase (DPYD) deficiency
- Prior chemotherapy is allowed as long as >28 days since the last administration and any toxicity has resolved to NCI CTCAE grade 1 or less
- Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trials results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dosing schedules 1 to 4
Dosing Group 1: - Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp) Dosing Group 2:
Dosing Group 3:
Dosing Group 4:
|
Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil.
Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
50 Gy/25#
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities
Time Frame: From Day 1 to Week 13
|
Used to determine the optimal dose and frequency of enadenotucirev that can be administered with chemoradiation.
Highest treatment schedule resulting in less than 30% dose limiting toxicity rate.
|
From Day 1 to Week 13
|
MRI tumour regression grade
Time Frame: Week 13
|
Used to determine the optimal dose and frequency of enadenotucirev that can be administered with chemoradiation. The MRI tumour regression grade uses the following scale and for the purposes of the trial analysis and dose escalation, scores of 1 or 2 will be classified as responders and scores of 3, 4 or 5 will be classified as non-responders:
|
Week 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability to deliver enadenotucirev concurrently with chemoradiation
Time Frame: Week 9
|
Treatment tolerance measured by proportion of patients completing at least 80% of the intended Capecitabine dose and at least 20 fractions of radiotherapy.
|
Week 9
|
MRI tumour regression grade
Time Frame: Week 13
|
To measure local response rate to combined therapy compared to pre-treatment status The MRI tumour regression grade uses the following scale and for the purposes of the trial analysis and dose escalation, scores of 1 or 2 will be classified as responders and scores of 3, 4 or 5 will be classified as non-responders:
|
Week 13
|
Pathological complete response rate
Time Frame: 4-6 weeks post surgery
|
To measure local response rate to combined therapy compared to pre-treatment status
|
4-6 weeks post surgery
|
Neoadjuvant Rectal (NAR) score
Time Frame: 4-6 weeks post surgery
|
To measure local response rate to combined therapy compared to pre-treatment status The Neoadjuvant Rectal (NAR) score ranges from 0-100 where a higher score equates to a worse prognosis. |
4-6 weeks post surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To analyse changes in circulating tumour DNA in response to chemoradiation and Enadenotucirev
Time Frame: Baseline (Pre 1st loading dose), week 4, week 13 and 4 to 6 week post surgery visit
|
ctDNA analysis will explore the clearance of ctDNA and any/or emerging changes in persisting ctDNA
|
Baseline (Pre 1st loading dose), week 4, week 13 and 4 to 6 week post surgery visit
|
To identify the 'proof of concept' that enadenotucirev replicates in the tumour.
Time Frame: Archival, Week 4 biopsy and Resection sample
|
Patients archival, week 4 biopsy and resection sample will be processed and stained for the presence of a hexon protein coat, viral gDNA.
This will identify the virus and allow confirmatory analysis (yes/no) to be completed to determine if the virus is only present within the tumour cells or not.
|
Archival, Week 4 biopsy and Resection sample
|
To analyse gene expression changes in rectal cancer in response to Enadenotucirev
Time Frame: Baseline (i.e. Archival), Week 4 biopsy and Resection sample
|
Patients archival, week 4 biopsy and resection sample will be processed using RNA sequencing to analyse whole genome RNA expression and nanostring gene expression
|
Baseline (i.e. Archival), Week 4 biopsy and Resection sample
|
To assess the changes in microbiome taxa during therapy
Time Frame: Baseline (pre-enad), End of week 1 / 2, End of week 4, End of week 7, Week 13
|
Extraction of DNA and 16S sequencing and meta-transcriptomics from faecal samples
|
Baseline (pre-enad), End of week 1 / 2, End of week 4, End of week 7, Week 13
|
Analyse the immune microenvironment as evidenced by immune cell infiltrates
Time Frame: Archival tumour tissue, Week 4 biopsy, Resection sample
|
Multiplex Immunohistochemistry of immune cell markers
|
Archival tumour tissue, Week 4 biopsy, Resection sample
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria Hawkins, MD FRCR MRCP, University of Oxford
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
Other Study ID Numbers
- OCTO_081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Rectal Cancer
-
Fondazione Policlinico Universitario Agostino Gemelli...Viewray Inc.UnknownLocally Advanced Rectal Cancer | Pathological Complete Response | Neoadjuvant ChemoradiotherapyItaly
-
University Hospital Southampton NHS Foundation...Cancer Research UK; IntraOp Medical Corporation; PLANETS Cancer CharityRecruitingLocally Advanced Rectal Cancer | Locally Recurrent Rectal CancerUnited Kingdom
-
St Vincent's University Hospital, IrelandRecruitingLocally Advanced Rectal Cancer | Pelvic Exenteration | Advanced Pelvic MalignancyIreland
-
Beijing Friendship HospitalChanghai Hospital; Peking Union Medical College Hospital; Peking University Cancer...Not yet recruitingLocally Advanced Rectal CancerChina
-
Sun Yat-sen UniversityAkeso; Haplox Biotechnology Co., Ltd.RecruitingLocally Advanced Rectal CancerChina
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced Rectal Cancer
-
Beijing Friendship HospitalPeking University First Hospital; Peking University People's Hospital; Peking... and other collaboratorsRecruitingLocally Advanced Rectal CancerChina
-
Zhejiang Cancer HospitalRecruiting
-
Fundación para el Fomento de la Investigación Sanitaria...Hospital General Universitario ElcheRecruiting
-
Gruppo Oncologico del Nord-OvestActive, not recruitingLocally Advanced Rectal CancerItaly
Clinical Trials on Enadenotucirev
-
Akamis BioCompletedPhase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)Metastatic Colorectal Cancer | Metastatic Bladder Cancer | Solid Tumours of Epithelial OriginBelgium, Spain
-
PsiOxus Therapeutics LtdCompletedRecurrent Platinum Resistant Ovarian CancerUnited Kingdom, Spain
-
Akamis BioBristol-Myers Squibb; Syneos HealthCompletedColorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Epithelial TumorUnited States